Gepotidacin – Oral Products

	Minimum Inhibitory Concentrations (mcg/mL)			Disk Diffusion (zone diameter in mm)
Pathogen	S	I	R	S	I	R
Enterobacteralesa, b	≤ 16	32	≥ 64	≥ 12	8-11	≤ 7
Staphylococcus saprophyticusb	≤0.25	-	-	≥ 23	-	-
Enterococcus faecalisb	≤4	-	-	≥ 14	-	-
Neisseria gonorrhoeaec	≤ 1	2	≥ 4	≥ 28	23-27	≤ 22

S = susceptible; I = intermediate; R = resistant
^a Clinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, and Citrobacter freundii complex.
^b Susceptibility interpretive criteria are based on a dose of 1500 mg twice daily.
^c Susceptibility interpretive criteria are based on a dose of 3000 mg followed by a second dose of 3000 mg approximately 12 hours later.